期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性粒细胞白血病急变为巨核细胞白血病合并骨髓纤维化1例 被引量：1

下载PDF
导出
摘要 急性巨核细胞白血病（acute megakaryocytic leukemia,AMLK）占急性髓系白血病发生率的3%-5%[1],由慢性粒细胞白血病（chronic myeloid leukemia,CML）急变为AMLK的比例报道不一,常常伴有骨髓纤维化,预后较差。现将我科诊治的1例CML合并骨髓纤维化发生急性巨核变报道如下。
作者 任会会 尚伟锋 黄丽芳 毛汉文 黄伟
机构地区 华中科技大学同济医学院附属同济医院
出处 《内科急危重症杂志》 2015年第1期79-80,共2页 Journal of Critical Care In Internal Medicine
基金 湖北省卫生厅临床医学资助项目(No:JX4B04) 武汉市卫生局临床医学科研项目(No:WX12A05)
关键词 慢性粒细胞白血病 急性巨核细胞白血病 骨髓纤维化
分类号 R557.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献2

二级参考文献25

  • 1Michael Deininger, Stephen G O'Brien, Francois Guilhot, et al. Inter- national randomized study of interferon vs STI571 (IRIS) 8-Year Fol- low up : sustained survival and low risk for progression or events in pa- tients with newly diagnosed chronic myeloid leukemia in chronic Phase ( CML - CP) treated with imatinib. Blood ( ASH Annual Meet- ing Abstracts) ,2009 (114) : 1126.
  • 2Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett,2007,249 ( 2 ) : 121-132.
  • 3Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004,305 ( 5682 ) : 399-401.
  • 4OHare T,Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant ima- tinib-resistant Abl kinase domain mutants. Cancer Res, 2005,65( 11 ) :4500-4505.
  • 5Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncolo- gist ,2008,13 (4) :424-434.
  • 6Porkka K, Koskenvesa P,Lundan T,et al. Dasatinib crosses the blood- brain barrier and is an efficient therapy for central nervous system Phila- delphia chromosome-positive leukemia. Blood,2008,112(4) : 1005-1012.
  • 7Baccarani M, Rosti G, Saglio G, et al. Dasatinib time to and durability of major and complete cytogenetic response ( MCyR and CCyR ) in patients with chronic myeloid leukemia in chronic phase (CML-CP). ASH Annual Meeting,2008(112) :450.
  • 8Apperley J, Cortes J, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol,2009,27(21 ) :3472-3479.
  • 9Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia,2008,22(12) :2176-2183.
  • 10Kantarjian H,Pasquini R,Levy V,et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily:two-year follow-up of a randomized phase 2 study ( START-R ). Cancer,2009,115 ( 18 ) :4136-4147.

共引文献17

同被引文献5

内科急危重症杂志
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部